CHICAGO (Reuters) - Controversy over popular diabetes pill Avandia took center stage on Monday at a meeting of the world’s experts on the disease, where researchers debated findings that the drug could boost heart-attack risk.The GlaxoSmithKline Plc drug has been under a cloud since an analysis published in the New England Journal of Medicine last month found taking Avandia led to a 43 percent boost in heart attack risk and a 64 percent rise in risk of heart death.
